Melanoma Clinical Trials in Phoenix

Showing 101-120 of 208 trials

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

NCT03110159

This is a pilot, phase 2, prospective, comparative study to evaluate the safety and efficacy of the combination of Levulan® Kerastick® for Topical Solution and blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator (LevulanPDT). The study hypothesis is that post solid organ transplantation patients, highly susceptible to non-melanoma skin cancer, can be treated safely and effectively through clinical cyclic application of PDT, lessening morbidity and possible mortality for this immunosuppressed patient population.

Skin CancerNon-melanoma Skin CancerSun Damaged Skin+1 more

Medical Dermatology Specialists8 participantsStarted Aug 2017

Phoenix, Arizona, United States

TERMINATEDPhase 1< 1 mile

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.

Breast CancerColorectal CancerOvarian Cancer+13 more

Atreca, Inc.87 participantsStarted Feb 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +16 more locations

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Melanoma Trials in Other Cities

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Study in Subjects With Small Primary Choroidal Melanoma

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Other Conditions in Phoenix